Benchmark Maintains Buy on Agilon Health, Raises Price Target to $13

Benchmark analyst Bill Sutherland has maintained a Buy rating on Agilon Health (NYSE: AGL) and increased the price target from $1.50 to $13. This adjustment reflects a positive outlook for the company's performance in the market.